Investors Launch Investigation Against NeoGenomics Over Potential Securities Fraud Allegations

Investor Alert: Pomerantz Law Firm Investigates NeoGenomics

Pomerantz LLP has initiated an investigation concerning NeoGenomics, Inc. (NASDAQ: NEO) related to allegations of possible securities fraud. This comes on the heels of disappointing financial disclosures from the company that have prompted concerns among investors.

Background on NeoGenomics

NeoGenomics, a leading provider of cancer-focused genetic testing services, released its second-quarter financial results on July 29, 2025. The report revealed a revenue of $181.3 million, significantly lower than earlier forecasts, coupled with a troubling net loss of $45.1 million. More critically, the company slashed its 2025 revenue outlook from approximately $753 million to a revised estimate of $720 million to $726 million.

In addition to a gloomy revenue forecast, NeoGenomics adjusted its EBITDA projections downward as well, further intensifying investor skepticism. The company now expects its adjusted EBITDA to fall between $41 million to $44 million, down from prior estimates ranging from $55 million to $58 million.

Impact on Stock Prices

Following the announcement of these results, NeoGenomics' stock took a considerable hit, declining by $1.21 per share or 18.73%, closing at $5.25 on the same day. Such a dramatic drop in stock price generally indicates that investors are highly concerned about the company's financial health and operational practices.

The Investigation Details

The investigation led by Pomerantz aims to uncover whether NeoGenomics and its officers or directors engaged in any fraudulent conduct or other illegal business activities that may have contributed to the recent financial downturn. Investors who believe they may have been affected by these developments are strongly encouraged to come forward and communicate with the firm.

Danielle Peyton, a representative from Pomerantz LLP, can be reached at 646-581-9980, extension 7980, or via email at [email protected].

About Pomerantz LLP

Established over 85 years ago, Pomerantz LLP is a renowned firm focused on corporate, securities, and antitrust class action litigation. The firm's founder, Abraham L. Pomerantz, was known as the dean of the class action bar and pioneered the field of securities class actions.

To date, Pomerantz has secured substantial multimillion-dollar recoveries for clients affected by securities fraud and corporate misconduct. The firm continues to advocate for the rights of investors, providing a platform for those impacted by potential fraud or breaches of fiduciary duty, maintaining its commitment to justice in the corporate sector.

For ongoing updates or potential involvement in the class action, interested parties can visit Pomerantz Law Firm's website.

This article serves as an investor alert and does not constitute legal advice.

Attorney advertising; prior results do not guarantee similar outcomes.